ClinicalTrials.gg
RecruitingNCT06169514MOXY-HSPUpdated Feb 6, 2026

Health Systems and Policy Contexts of Medical Oxygen

An observational study in Hypoxemia, Morality and Pneumonia, sponsored by Murdoch Childrens Research Institute. Recruiting at 6 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-06.

Sponsored by Murdoch Childrens Research Institute · Observational

From the registry’s dates

  • Started Jul 2024; still recruiting 2 years 3 months later.
Study type
Observational
Model
Other
Time perspective
Other
Enrollment
1
Ages
18 Years and older
Sex
All
01

Study summary

This is a mixed-methods program evaluation from a health systems and policy perspective, involving (i) stakeholder analysis, (ii) policy-implementation gap analysis, and (iii) comparative country case studies. This study aims to understand how national oxygen strategies achieve impact at national, and subnational level, across country contexts, at what cost.

The the investigators seek to:

  1. Involve policymakers, implementers (including private sector), and medical oxygen users in identifying challenges and understanding potential solutions to medical oxygen access;
  2. Generate new data on how medical oxygen systems work and can be improved from multiple perspectives;
  3. Draw lessons on medical oxygen that can directly inform national and global practice and policy.

This study will be conducted in 6 of the 9 countries participating in the Clinton Health Access Initiative (CHAI) led Medical Oxygen Implementation (MOXY) program (Uganda, Nigeria, Rwanda, Liberia, Lao PDR, Cambodia).

Key informants will be selected representing government, non-governmental agencies, professional associations, private sector, and civil society. This study will be completed over 4 years, with timelines varying between country study sites.

Read the detailed description

The investigators will use a concurrent mixed-methods design, with an overarching comparative case study methodology. The investigators will adopt an iterative approach, using co-design to adapt the study methodology to the specific context of each country and annual learning team meetings with stakeholders to refine the final case study topics (sub-study 3) and methodology.

Three embedded sub-studies are planned:

Sub-study 1 (Stakeholder Analysis) aims to understand the policy environment for medical oxygen services across different country contexts. This will be informed by the MOXY baseline survey, which includes data on oxygen-related facility readiness and clinical practices across the MOXY program areas. Data sources will include stakeholder interviews with participants from different levels (national, provincial, local) and policy perspectives (government, implementing/advising partners, practitioners, beneficiaries). Results will inform sub-study 2 and MOXY program implementation.

Sub-study 2 (Policy-Implementation Gap Analysis) aims to critically analyse the gap between policy intentions and actual implementation. This will be informed by the baseline facility readiness and clinical practice data. Data sources will include a desk review of oxygen-related policies, stakeholder in-depth interviews, and program administrative data. Results will inform implementation of country oxygen strategies and feed into prioritization of focus areas for sub-study 3.

Sub-study 3 (Comparative Country Case Studies) aims to compare oxygen programs across countries, focusing on particular challenges or unique solutions identified in sub-study 1 and 2. Data sources will include repeated desk review of oxygen-related policies and program administrative data, follow-up stakeholder interviews, and triangulation with quantitative survey results on facility readiness and clinical practices.

This research will also draw on national stakeholder dialogues - both to review, refine, and validate preliminary findings of the study team and to draw out feasible solutions/alternatives for both policy and practice and oxygen eco-system. In year 1 the investigators will generate key evidence about how the current strategies and polices are being translated into action, identifying key opportunities for implementing partners to focus support. Over years 2 and 3, the investigators will learn how these activities have affected medical oxygen service coverage, drawing lessons across country contexts and across different implementation approaches.

02

Conditions studied

  • Hypoxemia
  • Morality
  • Pneumonia

Keywords

  • Health system
  • Oxygen
  • Oxygen systems
  • Oxygen access
  • Pulse oximetry
03

In context

Hypoxia

1,076 studies on the registry are indexed under Hypoxia; 213 are open to participants now.

This study's planned enrollment of 1 is below the median of 79 across 277 observational studies indexed under Hypoxia.

Browse Hypoxia studies →

Lead sponsor

Murdoch Childrens Research Institute is the lead sponsor of 99 studies on the registry; 34 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 3 (60%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

This study will be conducted in 6 of the 9 countries participating in the CHAI-led MOXY program (Uganda, Nigeria, Rwanda, Liberia, Lao PDR, Cambodia).

Eligibility criteria

Key informants will be selected representing government, non-governmental agencies, professional associations, private sector, and civil society.

05

Study design

Observational model
Other
Time perspective
Other
Enrollment
1 participant (estimated)
Patient registry
No

Groups and cohorts

  • Policy and stakeholder analysis across 6 countries

    Policy and stakeholder analysis across 6 countries

    Other: No intervention

Interventions

  • OtherNo intervention

    No intervention

06

What researchers measure

Primary outcomes

  1. In-depth stakeholder interviews on national medical oxygen strategies

    In depth stakeholder interviews covering perspectives on policies, oversight, implementation, and related support towards the particular domain (e.g. measurement and indicators, health workforce capacity building, etc.)

    Time frame: 4 years

07

Study locations

6 of 6 sites recruiting
  • Cambodia
    Phnom Penh, Cambodia
    Recruiting
  • Lao PDR
    Vientiane, Laos
    Recruiting
    • Mayfong Mayxay, PhD · Contact
  • Liberia
    Monrovia, Liberia
    Recruiting
  • Nigeria
    Ibadan, Nigeria
    Recruiting
  • Rwanda
    Kigali, Rwanda
    Recruiting
  • Uganda
    Kampala, Uganda
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2024 (actual). Primary completion is estimated for Dec 2027, 41 months after the start.

Of 125 non-industry observational studies under Hypoxia, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 74. This study's planned 41 months is above that.

Counting every sponsor, half of 155 studies reached it within 14 months; a quarter within 3 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 29, 2023
First posted
Dec 13, 2023
StartActual
Jul 31, 2024
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2027
Last update
Feb 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06169514
Lead sponsor
Murdoch Childrens Research Institute
Collaborators
University of Ibadan, University of Health Sciences, Lao People's Democratic Republic (PDR), University of Health Sciences, Cambodia, Makerere University, Ministry of Health, Liberia, Ministry of Health, Rwanda, Karolinska Institutet
Responsible party
Sponsor
First posted
Dec 13, 2023
Start date
Jul 31, 2024
Primary completion
Dec 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Feb 6, 2026

Study contacts

Rami Subhi, MBBS, FRACS, MD (Res)
Contact
rami.subhi@mcri.edu.au
+61403151186
Hamish Graham, PhD
Contact
hamish.graham@rch.org.au
+61403456262
Hamish Graham, PhD
principal investigator · Murdoch Childrens Research Institute
Carina King, PhD
principal investigator · Karolinska Institutet

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion